IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider | Kabir Nath


Listen Later

Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. 

For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. 

Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.

...more
View all episodesView all episodes
Download on the App Store

IDEA Collider: Innovation & Asymmetric Learning in PharmaBy IDEA Pharma

  • 5
  • 5
  • 5
  • 5
  • 5

5

2 ratings


More shows like IDEA Collider: Innovation & Asymmetric Learning in Pharma

View all
Odd Lots by Bloomberg

Odd Lots

1,768 Listeners

The Daily by The New York Times

The Daily

111,083 Listeners

The Readout Loud by STAT

The Readout Loud

319 Listeners

FT News Briefing by Financial Times

FT News Briefing

700 Listeners

The Journal. by The Wall Street Journal & Gimlet

The Journal.

5,920 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

31 Listeners

People I (Mostly) Admire by Freakonomics Radio + Stitcher

People I (Mostly) Admire

2,143 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,313 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

11 Listeners

The Rest Is Politics by Goalhanger

The Rest Is Politics

3,096 Listeners

The Top Line by Fierce Life Sciences

The Top Line

12 Listeners

The Rest Is Politics: US by Goalhanger

The Rest Is Politics: US

2,241 Listeners

The BioCentury Show by BioCentury

The BioCentury Show

11 Listeners

The Economics Show by Financial Times

The Economics Show

96 Listeners

Cures & Capital by Martin Slezak and Simon Birksø

Cures & Capital

2 Listeners